These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18437428)

  • 1. Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH.
    Rianthavorn P; Cain JP; Turman MA
    Pediatr Nephrol; 2008 Aug; 23(8):1367-70. PubMed ID: 18437428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
    Potts MB; DeGiacomo AF; Deragopian L; Blevins LS
    Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of conivaptan for refractory syndrome of inappropriate secretion of antidiuretic hormone in a pediatric patient.
    Peters S; Kuhn R; Gardner B; Bernard P
    Pediatr Emerg Care; 2013 Feb; 29(2):230-2. PubMed ID: 23546432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
    Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K
    Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
    Breshears JD; Jiang B; Rowland NC; Kunwar S; Blevins LS
    Clin Neurol Neurosurg; 2013 Nov; 115(11):2358-61. PubMed ID: 24041963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conivaptan for hyponatremia in the neurocritical care unit.
    Wright WL; Asbury WH; Gilmore JL; Samuels OB
    Neurocrit Care; 2009; 11(1):6-13. PubMed ID: 19003543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
    Murphy T; Dhar R; Diringer M
    Neurocrit Care; 2009; 11(1):14-9. PubMed ID: 19123060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
    Gargani L; Schmidt PH; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1505-13. PubMed ID: 22103869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
    Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
    Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
    Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
    Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
    Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.
    Annane D; Decaux G; Smith N;
    Am J Med Sci; 2009 Jan; 337(1):28-36. PubMed ID: 19057376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous conivaptan.
    Moen MD; Keating GM
    Am J Cardiovasc Drugs; 2008; 8(5):341-8; discussion 349. PubMed ID: 18828645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W; Głuszek J
    Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
    Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of euvolemic hyponatremia attributed to SIADH in the hospital setting.
    Peri A; Giuliani C
    Minerva Endocrinol; 2014 Mar; 39(1):33-41. PubMed ID: 24513602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.
    Tuli G; Tessaris D; Einaudi S; De Sanctis L; Matarazzo P
    J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):288-292. PubMed ID: 28515029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia.
    Metzger BL; DeVita MV; Michelis MF
    Int Urol Nephrol; 2008; 40(3):725-30. PubMed ID: 18363040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conivaptan: new treatment for hyponatremia.
    Walter KA
    Am J Health Syst Pharm; 2007 Jul; 64(13):1385-95. PubMed ID: 17592003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.